Einloggen

Thematische Bibliographien / Vitiligo surgery / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Vitiligo surgery.

Zeitschriftenartikel zum Thema „Vitiligo surgery“

Autor: Grafiati

Veröffentlicht am 1. Juli 2021

Zuletzt aktualisiert am 1. Februar 2022

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Vitiligo surgery" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Ashwini, PK, DJ Sushmitha und S. Veeranna. „Vitiligo with special emphasis on vitiligo surgery“. Archives of Medicine and Health Sciences 8, Nr. 1 (2020): 140. http://dx.doi.org/10.4103/amhs.amhs_50_20.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Mulekar, SanjeevV. „Evolution of vitiligo surgery“. Pigment International 3, Nr. 2 (2016): 61. http://dx.doi.org/10.4103/2349-5847.196292.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Nahhas, Amanda F., Tasneem F. Mohammad und Iltefat H. Hamzavi. „Vitiligo Surgery: Shuffling Melanocytes“. Journal of Investigative Dermatology Symposium Proceedings 18, Nr. 2 (Oktober 2017): S34—S37. http://dx.doi.org/10.1016/j.jisp.2017.01.001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Mulekar, Sanjeev V., Ahmed Al Issa, Marwan Asaad, Bassel Ghwish und Abdullah Al Eisa. „Mixed Vitiligo“. Journal of Cutaneous Medicine and Surgery 10, Nr. 2 (März 2006): 104–7. http://dx.doi.org/10.2310/7750.2006.00018.

Der volle Inhalt der Quelle

Annotation:

Background: There are two commonly recognized forms of vitiligo—generalized and localized. This classification is important to understand the course of the disease and its prognosis. Most patients have generalized vitiligo; few patients have both segmented and generalized vitiligo. Observation: We report four more cases of mixed vtiligo, segmental with generalized type. This report is only the second to present a case of segmental with generalized vitiligo. Conclusion: Mixed vitiligo is not yet part of a standard classification. Its etiology is not yet fully defined. Further research is required to understand the course and prognosis of mixed vitiligo.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Khurrum, Huma, und Khalid M. AlGhamdi. „The Relationship Between the Serum Level of Vitamin D and Vitiligo“. Journal of Cutaneous Medicine and Surgery 20, Nr. 2 (12.10.2015): 139–45. http://dx.doi.org/10.1177/1203475415610071.

Der volle Inhalt der Quelle

Annotation:

Background: Low vitamin D levels have been associated with several autoimmune diseases. Vitiligo could be associated with low vitamin D levels. Objective: To determine the level of serum vitamin D in vitiligo patients compared to controls and reveal the possible association of vitamin levels with the pathogenesis of vitiligo. Patients and Methods: A case-controlled study was conducted. After excluding factors that may affect serum vitamin D levels, blood samples were taken from vitiligo patients and controls. The association between vitamin D levels and various vitiligo subgroups (duration of vitiligo, site of onset, age, etc) was measured and correlated. Results: A total of 150 vitiligo patients, 90 (60%) males with a mean age of 30.6 ± 11.4 years, were recruited. The study also had 150 age- and gender-matched vitiligo-free control subjects. There was no significant difference in median serum vitamin D levels between the cases and the controls ( P = .25). The serum levels of vitamin D of the vitiligo patients were found to be lower in males ( P = .01), the younger age group ( P = .01), and patients not treated with ultraviolet (UV) treatment ( P = .01). Conclusion: There is no difference between the vitamin D levels of the vitiligo patients and the control subjects. However, deficiency of 25(OH)D levels within the vitiligo subgroups may be linked to younger age, male gender, short duration of vitiligo, and non-use of phototherapy.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Yazdanpanah, Mohammad Javad, Seyed Ali Seyedi Noghabi, Morteza Taghavi, Monavar Afzal Aghaee und Naghmeh Zabolinejad. „Comparison of Autoimmune Thyroid Disease in Patients With Progressive and Stable Vitiligo“. Journal of Cutaneous Medicine and Surgery 20, Nr. 2 (28.08.2015): 135–38. http://dx.doi.org/10.1177/1203475415604551.

Der volle Inhalt der Quelle

Annotation:

Background and Objective: Activity of vitiligo has not been considered as a patient selection criteria in previous studies; we decided to compare the presence of elevated thyroid auto-antibodies in patients with progressive and stable vitiligo. Methods: Seventy-two patients with vitiligo were examined for thyroid problems and were divided into 2 groups of stable and progressive vitiligo according to their history and physical examination. Anti-thyroid peroxidase antibodies (anti-TPO antibodies), thyroxine (T4), and thyroid stimulating hormone (TSH) levels were assessed for all patients. Results: Elevated levels of anti-TPO antibodies were observed in 43.7% of the patients with stable vitiligo and in 37.5% of patients with progressive vitiligo, which was not statistically significant ( P = .315). Conclusion: This study not only confirmed thyroid dysfunction in patients with vitiligo but also showed that there was no difference in thyroid dysfunction and anti-TPO antibody levels in the subgroups of patients with stable or progressive vitiligo.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Alghamdi, Khalid M., Noura A. Moussa, Ahmed Mandil, Maha Alkofidi, Abdulaziz Madani, Nojoud Aldaham und Abbas A. Alkamel. „Public Perceptions and Attitudes Toward Vitiligo“. Journal of Cutaneous Medicine and Surgery 16, Nr. 5 (September 2012): 334–40. http://dx.doi.org/10.1177/120347541201600510.

Der volle Inhalt der Quelle

Annotation:

Background: Previous studies have discussed attitudes of vitiligo patients toward their disease. However, no studies have addressed this issue from the public's point of view. Objective: To explore the perceptions, attitudes, and misconceptions of the public toward vitiligo. Methods: A self-administered questionnaire was distributed to attendees of primary health care centers in Riyadh, Saudi Arabia, between January and August 2010. Results: Overall, 924 of the 1,000 distributed questionnaires were returned, and 429 were males (46.8%). Moreover, 33.1% (303 of 916) believed that vitiligo is contagious or did not know that it is not. The cause of vitiligo was thought to be infectious by 20.4% of respondents (182 of 894), inherited by 40.5% (365 of 902), autoimmune by 41.2% (370 of 899), and due to a lack of hygiene by 22.5% (199 of 883). Unmarried individuals and those with less education were more likely to state that vitiligo is caused by an infection ( p = .02, p = .03, respectively). Younger individuals and those with less education were more likely to think that vitiligo is caused by a lack of hygiene ( p = .01, p = .001, respectively). More than half of the participants (56.1%, 504 of 898) would be unwilling to marry a vitiligo patient. Younger individuals and males were less likely to marry a vitiligo patient ( p = .01, p = .05, respectively), whereas those of lower income were more likely to accept it ( p = .002). Conclusions: Various misconceptions and negative attitudes about vitiligo among the public are prevalent. Educating the public about vitiligo could ultimately lead to better psychosocial well-being of vitiligo patients. Contexte: Des études ont déjà porté sur la perception des personnes atteintes de vitiligo à l'égard de leur propre maladie, mais aucune étude n'a porté sur la perception du public à l'égard de cette maladie. Objectif: L'étude visait à analyser les perceptions, les attitudes, et les idées fausses du public à l'égard du vitiligo. Méthodes: Un questionnaire autoadministré a été remis à des personnes présentes dans des centres de soins primaires à Riyad, en Arabie saoudite, entre janvier et août 2010. Résultats: En tout, 924 questionnaires sur 1,000 ont été remis. Sur ce nombre, 429 avaient été remplis par des hommes (46.8%). De plus, 33.1% (303 sur 916) des répondants croyaient que le vitiligo était contagieux ou ne savaient pas qu'il ne l'était pas. Quant à la cause du vitiligo, 20.4% des participants (182 sur 894) croyaient que c'était une maladie contagieuse; 40.5% (365 sur 902), que c'était une maladie héréditaire; 41.2% (370 sur 899), que c'était une maladie auto-immune; et 22.5% (199 sur 883), que c'était une maladie due à un manque d'hygiène. Les personnes célibataires et celles moins instruites étaient plus portées à croire que le vitiligo était causé par une infection ( p = .02 et p = .03, respectivement). Les jeunes et les personnes moins instruites étaient plus susceptibles de croire que le vitiligo était causé par un manque d'hygiène ( p = .01 et p = .001, respectivement). Plus de la moitié des participants (56.1%, 504 sur 898) ne voulaient pas se marier avec une personne atteinte de vitiligo. Les jeunes et les hommes étaient moins disposés à se marier avec une personne atteinte de vitiligo ( p = .01 et p = .05, respectivement), tandis que ceux à faible revenu étaient plus susceptibles d'accepter le fait ( p = .002). Conclusions: Il existe plusieurs idées fausses sur le vitiligo au sein de la population, et la maladie suscite des réactions négatives. L'éducation du public sur le vitiligo pourrait peut-être améliorer le bien-être psychosocial des personnes atteintes de vitiligo.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Hann, Seung-Kyung, Dunlu Chen und Jean-Claude Bystryn. „Systemic Steroids Suppress Antimelanocyte Antibodies in Vitiligo“. Journal of Cutaneous Medicine and Surgery 1, Nr. 4 (April 1997): 193–95. http://dx.doi.org/10.1177/120347549700100403.

Der volle Inhalt der Quelle

Annotation:

Background: Vitiligo is associated with autoantibodies to melanocytes. The role of these antibodies in the pathogenesis of the disease is still unknown. Objective: The purpose of this study was to examine the role of vitiligo antibodies in the pathogenesis of the disease by studying whether or not there is a correlation between changes in their level and response to therapy with systemic steroid. Methods: Antibodies to the 40 to 45 kD, 75 kD, and 90 kD vitiligo antigens were measured prior to and following systemic steroid therapy in 10 patients with active vitiligo. Results: Four months following initiation of therapy, seven (78%) of nine patients with good clinical response to steroid treatment had a significant decrease in the level of vitiligo antibodies. By contrast, one patient who had no response to treatment had a slight increase in antibody levels. Conclusion: These findings suggest that one mechanism by which corticosteroids can cause repigmentation in vitiligo is by decreasing the level of vitiligo antibodies, and support the notion that vitiligo antibodies are involved in the pathogenesis of this disease.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Kanwar, Amrinder J., Rahul Mahajan und Davinder Parsad. „Effect of Age at Onset on Disease Characteristics in Vitiligo“. Journal of Cutaneous Medicine and Surgery 17, Nr. 4 (Juli 2013): 253–58. http://dx.doi.org/10.2310/7750.2013.12075.

Der volle Inhalt der Quelle

Annotation:

Background: Vitiligo is a multifactorial disease in which genetic, immunologic, and environmental factors play an important part. Late-onset vitiligo is a poorly defined entity. Materials and Methods: Case records of patients who attended the pigmentary clinic at our institute from January 2001 to December 2010 were reviewed. Patients with a diagnosis of vitiligo were analyzed with respect to their demographic characteristics with special reference to their age at onset. Results: Patients with disease onset after 30 years had a significantly higher association with precipitating factors such as trauma, stress, and drugs in comparison with early-onset vitiligo ( p < .004). However, the difference did not reach statistical significance when these factors were analyzed individually. There was a significantly higher association with other nonautoimmune diseases ( p = .05), a higher incidence of positive family history ( p < .0001), and a higher association with leukotrichia ( p < .002) in late-onset disease. Early-onset nonsegmental vitiligo was associated with a higher incidence of photosensitivity and pruritus compared to early-onset segmental vitiligo. Conclusion: Late-onset vitiligo has certain distinguishing features compared to early-onset vitiligo.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Yu, Richard, Yuanshen Huang, Xuejun Zhang und Youwen Zhou. „Potential Role of Neurogenic Inflammatory Factors in the Pathogenesis of Vitiligo“. Journal of Cutaneous Medicine and Surgery 16, Nr. 4 (Juli 2012): 230–44. http://dx.doi.org/10.1177/120347541201600404.

Der volle Inhalt der Quelle

Annotation:

Background: Vitiligo is a highly complex multifactorial condition of the skin that has an unclear mechanism of pathogenesis. Objective: This review summarizes the role of various neurogenic inflammatory factors significantly upregulated in vitiligo. Methods: A literature review was conducted of all pertinent data regarding neuropeptides that are altered in vitiligo and their possible role in the destruction of melanocytes. Results: The close associations between the skin, immune system, and nervous system, along with specific changes demonstrated in vitiligo patients, support a pathogenic mechanism of vitiligo that involves neuroimmunologic factors, the release of which can be governed by mental stress. Conclusion: Neuropeptides and nerve growth factors are critical regulators of emotional response and may precipitate the onset and development of vitiligo in certain predisposed individuals. More studies are required to investigate whether a direct link exists between genetics, mental stress, and neurogenic factors in vitiligo.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Kambhampati, Bala Naga Sindhura, Gitesh U. Sawatkar, Muthu Sendhil Kumaran und Davinder Parsad. „Congenital Vitiligo“. Journal of Cutaneous Medicine and Surgery 20, Nr. 4 (27.01.2016): 354–55. http://dx.doi.org/10.1177/1203475416629132.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Khurrum, Huma, Khalid M. AlGhamdi und Essam Osman. „Screening of Glaucoma or Cataract Prevalence in Vitiligo Patients and Its Relationship With Periorbital Steroid Use“. Journal of Cutaneous Medicine and Surgery 20, Nr. 2 (27.10.2015): 146–49. http://dx.doi.org/10.1177/1203475415615325.

Der volle Inhalt der Quelle

Annotation:

Background/Aim: There is scarce literature connecting vitiligo and primary open angle glaucoma (POAG). Most literature reports that secondary complications are a direct consequence of corticosteroid treatment of vitiligo. In this study, we aimed to investigate the prevalence of ocular problems in patients with vitiligo and to determine its association with periorbital topical corticosteroid use. Method: A cross-sectional study was carried out on 90 patients with vitiligo. The Vitiligo European Task Force questionnaire was completed for each patient. A control group comprising 90 healthy individuals who did not have vitiligo and who were matched on age and gender was used for comparison. A complete ophthalmologic examination was performed. A family history of glaucoma and the use of topical steroids were recorded. Results: Two (2/90, 2.2%) of the patients with vitiligo had glaucoma compared with none of the individuals in the control group ( P = .25). Nineteen of the 90 patients with vitiligo used periorbital steroids, and of these patients, 10.5% (2/19) developed glaucoma. The duration of periorbital corticosteroid use was 4.50 ± 2.1 years. Eighty-nine percent (17/19) of the vitiligo patients who applied the potent topical corticosteroid (class I) clobetasol propionate to the periorbital area did not develop glaucoma. In contrast, glaucoma was not observed in 79% (71/90) of the vitiligo patients who did not use steroids. Cataract, uveitis, or fundus problems were not observed in either group. Conclusion: The study suggests that patients who have vitiligo and use topical steroids periorbitally do not have an increased risk of glaucoma or cataracts. Future studies that have a larger sample size and use a detailed steroid use protocol are needed.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Sawchuk, Michael, Frank Spano, Wei Jing Loo und Lyn Guenther. „The Coexistence of Psoriasis and Vitiligo: A review“. Journal of Cutaneous Medicine and Surgery 16, Nr. 5 (September 2012): 300–305. http://dx.doi.org/10.1177/120347541201600505.

Der volle Inhalt der Quelle

Annotation:

Background: Psoriasis and vitiligo are both autoimmune diseases with an increased incidence noted in genetic relatives. They share similar trigger factors and have been observed to coexist in individuals. Objective: The purpose was to review the literature on the coexistence of psoriasis and vitiligo and to determine if there is a higher than expected prevalence of psoriasis in patients with vitiligo and vice versa. Methods: A literature review was conducted using Medline, EMBASE, and the Cochrane Library from 1968 to 2010. All articles that included reports of individuals with both psoriasis and vitiligo in the English language were documented. Results: We identified 338 articles, among which 35 case reports and 7 case series were mentioned. For each case series, the prevalence of psoriasis in patients with vitiligo, or vice versa, falls within the prevalence range of the background population on which the study was based. Conclusion: An increase in the expected prevalence of psoriasis in individuals with vitiligo, or vice versa, was not found in our study, suggesting that the coexistence of the two diseases appears to be due to chance alone. Large epidemiologic studies are required to address with certainty whether psoriasis is more common in individuals with vitiligo and vice versa. Renseignements de base: Le psoriasis et le vitiligo sont deux affections auto-immunes qui ont une incidence accrue observée chez les membres de la famille apparentée. Ils partagent des facteurs déclencheurs similaires, et des études ont démontré leur coexistence chez les personnes. Objectif: Le but était de faire une analyse documentaire sur la coexistence du psoriasis et du vitiligo et de déterminer s'il y a une prévalence plus élevée que prévu du psoriasis chez les patients atteints de vitiligo et vice versa. Méthodes: Une analyse documentaire a été effectuée en utilisant Medline, EMBASE, et la Cochrane Library de 1968 à 2010. Tous les articles comportant des rapports sur des personnes souffrant à la fois de psoriasis et de vitiligo rédigés en anglais ont été documentés. Résultats: Nous avons trouvé 338 articles, parmi lesquels 35 exposés de cas et 7 séries de cas ont été mentionnés. Pour chaque série de cas, la prévalence du psoriasis chez les patients atteints de vitiligo, ou vice versa, s'inscrit dans la fourchette de prévalence de la population de base qui a fait l'objet de l'étude. Conclusion: Notre étude n'a pas démontré une augmentation de la prévalence de psoriasis attendue chez les personnes atteintes de vitiligo, ou vice versa, ce qui suggère que la coexistence des deux affections semble être due au seul hasard. D'importantes études épidémiologiques sont nécessaires pour démontrer avec certitude que le psoriasis est plus fréquent chez les personnes atteintes de vitiligo et vice versa.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Relke, Nicole, und Melinda Gooderham. „The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature“. Journal of Cutaneous Medicine and Surgery 23, Nr. 3 (22.03.2019): 298–306. http://dx.doi.org/10.1177/1203475419833609.

Der volle Inhalt der Quelle

Annotation:

Vitiligo is a common acquired depigmenting disorder characterized by the development of white macules and patches due to the loss of melanocytes. Patients with vitiligo can be stigmatized by society, making the disease a source of psychological stress that can considerably affect quality of life. The goal of vitiligo treatment is to obtain skin repigmentation in the majority of cases, and less commonly to depigment the remaining normal skin. There is no consistent, long-term, durable therapy for vitiligo for all patients, highlighting the unmet need for new safe and effective therapies to control this disease. Recently, JAK inhibitors have been explored as a promising novel treatment option in vitiligo. The JAK and signal transducers and activators of transcription (STAT) pathway is an attractive therapeutic target because IFN-γ–dependent cytokines produced through this pathway have been implicated in the pathogenesis of disease. This literature review describes vitiligo pathophysiology, explains the usefulness of the JAK inhibitors for treatment, and summarizes published case reports, case series, and open-label studies. Research outlined here shows JAK inhibitors in patients with vitiligo have a favorable safety profile and effectively produce repigmentation of lesions, especially with concomitant ultraviolet exposure. Additional studies are required to confirm efficacy, establish safety, and investigate durability of repigmentation.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Al-Mutairi, Nawaf, und Azari Al-Doukhi. „Familial Coexisting and Colocalized Psoriasis and Vitiligo Responding to Alefacept“. Journal of Cutaneous Medicine and Surgery 13, Nr. 3 (Mai 2009): 172–75. http://dx.doi.org/10.2310/7750.2008.08023.

Der volle Inhalt der Quelle

Annotation:

Background: Psoriasis is an immune-mediated, chronic, inflammatory disease that significantly impairs both physical and emotional aspects of an individual's quality of life. Vitiligo leads to depigmentation of skin, in which some or all melanocytes in the interfollicular epidermis and occasionally those in the hair follicles are selectively destroyed. The coexistence of the two disorders is rarely seen. Objective: To report two cases of the rare coexistence of psoriasis and vitiligo in a family. Methods: After providing informed written consent, both patients were given alefacept 15 mg/kg weekly injections for 12 weeks. The patients were monitored both clinically and with all relevant laboratory investigations. These patients were then followed up once a month for 2 years. Results: Treatment with alefacept led to complete clearance of vitiligo along with the expected improvement in psoriasis. In the 2-year follow-up, vitiligo did not recur, although psoriasis relapsed and was appropriately treated. Conclusion: Use of alefacept in vitiligo may turn out to be a possible novel off-label treatment option in vitiligo. But the results need to be reproduced in larger studies

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Zedan, Hatem, Amira Ali Abdel-Motaleb, Nahed Mahmoud Ali Kassem, Heba Ahmed Abdel Hafeez und Mahmoud Rezk Abdelwhahed Hussein. „Low Glutathione Peroxidase Activity Levels in Patients with Vitiligo“. Journal of Cutaneous Medicine and Surgery 19, Nr. 2 (März 2015): 144–48. http://dx.doi.org/10.2310/7750.2014.14076.

Der volle Inhalt der Quelle

Annotation:

Background Vitiligo is an idiopathic skin disease characterized by white areas on the skin due to loss of the functional melanocytes, with possible involvement of oxidative stress. Glutathione peroxidase (GPx) is an antioxidant enzyme that protects cells against oxidative damage. Aim To examine serum GPx levels in patients with vitiligo and to relate the findings to the clinical features. Patients and Methods The study group included 60 patients with vitiligo and 30 matching healthy controls. GPx activity was evaluated using enzyme-linked immunosorbent assay. Results We found a significant decrease in serum GPx activity level in the patients with vitiligo compared to the healthy controls (0.29 ± 0.14 versus 0.47 ± 0.13, p < .001). The levels were significantly low in skin phenotypes III and IV ( p < .001). Higher levels were also observed with increasing age (≥ 14 years), prolonged disease duration (≥ 3 years), and generalized and extensive vitiligo (<50%). However, these variations were statistically insignificant. Conclusions Low levels of serum GPx activity, indicative of a disturbed oxidant-antioxidant system, may contribute to the development of vitiligo.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Anitha, B. „From the Literature in Vitiligo Surgery“. Journal of Cutaneous and Aesthetic Surgery 4, Nr. 1 (2011): 70. http://dx.doi.org/10.4103/0974-2077.79204.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

AlGhamdi, Khalid M., Huma Khurrum und Ammar Rikabi. „Worsening of Vitiligo and Onset of New Psoriasiform Dermatitis following Treatment with Infliximab“. Journal of Cutaneous Medicine and Surgery 15, Nr. 5 (September 2011): 280–84. http://dx.doi.org/10.2310/7750.2011.10068.

Der volle Inhalt der Quelle

Annotation:

Background: Vitiligo is a depigmentation disorder caused by melanocyte destruction that possibly results from an autoimmune mechanism. Psoriasis is an immune-mediated, chronic, inflammatory dermatosis. Although tumor necrosis factor α antagonists (anti-TNF-α), such as infliximab, are effective in treating psoriasis, many cases reported in the literature indicate that psoriasis might also be induced by treatment with infliximab. Some studies also suggest that TNF-α antagonists might be an effective treatment for vitiligo because the disorder is characterized by increased levels of TNF-α, indicating that it might play a role in the pathogenesis of this disease. Objective: We report a case of psoriasiform dermatitis with vacuolar interface reaction that occurred after infliximab therapy in a patient with vitiligo. Method: A 17-year-old male patient with vitiligo vulgaris was treated with an intravenous infusion of 5 mg/kg of infliximab at 0, 2, and 6 weeks and then once every 6 weeks over a span of 6 months. The patient was monitored both clinically and with laboratory investigations. He had no personal or family history of psoriasis. He tolerated the treatment well, without side effects. However, he developed a biopsy-proven psoriasiform lesion for the first time 4 months after he completed his sixth dose of infliximab. His vitiligo also worsened. Conclusion: This case report shows that infliximab given for vitiligo did not improve the disorder and that the vitiligo actually progressed. Moreover, psoriasiform lesions developed after this therapy. Further studies are needed to identify the effects of infliximab in patients with vitiligo.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Sawicki, Jakub, Sanjay Siddha und Cheryl Rosen. „Vitiligo and Associated Autoimmune Disease: Retrospective Review of 300 Patients“. Journal of Cutaneous Medicine and Surgery 16, Nr. 4 (Juli 2012): 261–66. http://dx.doi.org/10.1177/120347541201600408.

Der volle Inhalt der Quelle

Annotation:

Background: Vitiligo, the most common cutaneous depigmentation disorder, has reported associations with other autoimmune diseases. However, literature on the strengths of the associations is conflicting, and no data on the subject exist from a Canadian population. Objective: To determine autoimmune disease associations with vitiligo and which, if any, screening bloodwork is appropriate in vitiligo patients. Methods: A retrospective review of vitiligo patients admitted to the Toronto Western Hospital phototherapy unit was conducted from January 1, 2000, to August 30, 2009. Data regarding patient characteristics, vitiligo clinical features (family history, age at onset, type, extent), associated diseases in the patient and family, and admission bloodwork (hemoglobin, vitamin B12, thyroid-stimulating hormone [TSH], antinuclear antibody) were recorded and compared, using the Fisher exact test where applicable. Results: A total of 300 patient charts were reviewed (average age 41.5 ± 15.5 years; 47% male, 53% female). Hypothyroidism was present in 12.0% and pernicious anemia in 1.3% of patients—significant increases over the population prevalence. No other differences in prevalence were seen compared to the general population. TSH was increased in 3.7% of patients without a history of hypothyroidism. Hemoglobin and vitamin B12 were decreased in 0.3% of vitiligo patients without a history of pernicious anemia. Conclusion: We found a significantly higher prevalence of hypothyroidism and pernicious anemia in vitiligo patients.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Wiwanitkit, Viroj. „Mercury and Vitiligo“. Journal of Cutaneous Medicine and Surgery 16, Nr. 6 (November 2012): 387. http://dx.doi.org/10.1177/120347541201600605.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Malhotra, Neel, und Marlene Dytoc. „The Pathogenesis of Vitiligo“. Journal of Cutaneous Medicine and Surgery 17, Nr. 3 (Mai 2013): 153–72. http://dx.doi.org/10.2310/7750.2012.12005.

Der volle Inhalt der Quelle

Annotation:

Background: Vitiligo is a commonly encountered pigmentary disorder. Numerous studies and investigations from all over the world have attempted to determine the mechanisms behind this disease; however, the pathogenesis of vitiligo remains elusive. Objective: In this comprehensive review article, we present the findings behind the five overarching theories of what causes this disfiguring and psychologically debilitating disease. Method: We begin our discussion with the role of genetic predisposition and move onward to the neural theory first proposed in the 1950s. Next we discuss the autoimmune hypothesis, followed by the reactive oxygen species model, and conclude by describing the findings of the more recent melanocytorrhagy hypothesis. Conclusion: Although the exact pathogenesis of vitiligo is uncertain, each of these theories likely plays a role. Understanding each theory would pave the way for therapeutic advances for this disease.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Langley, Annie R., Paul Manley und Yuka Asai. „A Case of Colocalized Vitiligo and Psoriasis“. Journal of Cutaneous Medicine and Surgery 20, Nr. 2 (28.10.2015): 150–52. http://dx.doi.org/10.1177/1203475415615326.

Der volle Inhalt der Quelle

Annotation:

Background: Psoriasis and vitiligo are common dermatologic conditions with underlying autoimmune etiologies. There are few reports of concomitant and colocalized disease. Several theories have been proposed to explain this rare presentation. Objective: The objective of this study was to present a rare case of a concomitant and colocalized presentation of vitiligo and psoriasis. Methods: Case report. Results: A 72-year-old male was referred for treatment of a 30-year history of psoriasis and 5-year history of colocalized vitiligo. The patient had no other underlying autoimmune diseases including psoriatic arthritis. Conclusion: Clinicians should be aware of the possible concomitance and colocalization of psoriasis and vitiligo. Further research is needed to elucidate the common pathways leading to the concomitance and colocalization of these diseases.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Al-Shobaili, Hani A. „Treatment of Vitiligo Patients by Excimer Laser Improves Patients’ Quality of Life“. Journal of Cutaneous Medicine and Surgery 19, Nr. 1 (Januar 2015): 50–56. http://dx.doi.org/10.2310/7750.2014.14002.

Der volle Inhalt der Quelle

Annotation:

Background: Vitiligo can negatively affect patients’ quality of life (QoL). Assessment of QoL provides relevant information about treatment benefits. Objectives: To examine the effects of excimer laser treatment on vitiligo patients’ QoL and to identify overall patient satisfaction. The literature review failed to show any study concerning the same field. Methods: A total of 134 vitiligo patients (with 386 lesions) were studied. The Dermatology Life Quality Index (DLQI) was used to assess the effect of excimer laser treatment on patients’ QoL. A visual analogue scale (VAS) was used to rate patients’ overall life satisfaction and disturbance. Results: Excimer laser treatment significantly improved QoL in vitiligo patients, with improvement observed in five of six DLQI domains. Treatment-induced changes in the VAS score showed a significant decline in life disturbance and improvement in life satisfaction. Multivariate analysis revealed that sex and treatment duration were independent factors influencing treatment outcomes. Conclusions: Treatment of vitiligo with excimer laser can positively influence patients’ QoL. Patients with multiple focal lesions should be treated by excimer laser even if some lesions may not show significant clinical improvement.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Gerstner, Gervaise L., und Alan Matarasso. „Surgical Management of Vitiligo“. Plastic and Reconstructive Surgery 120, Nr. 5 (Oktober 2007): 1430–31. http://dx.doi.org/10.1097/01.prs.0000280564.25786.bf.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Yazdanpanah, Mohammad Javad, Mahnaz Banihashemi, Fakhrozaman Pezeshkpoor, Mehri Moradifar, Shahab Feli und Habibollah Esmaeili. „Evaluation between Association of Psoriasis and Vitiligo“. Journal of Cutaneous Medicine and Surgery 19, Nr. 2 (März 2015): 140–43. http://dx.doi.org/10.2310/7750.2014.14074.

Der volle Inhalt der Quelle

Annotation:

Background Although the occurrence of psoriasis and vitiligo is reported in a few studies, no proper relationship has been found between these two diseases. Objective The aim of this study was to identify the frequency of the coincidence of these two diseases. Method A descriptive and cross-sectional study was conducted on 6,200 patients referred to dermatology clinics from September 2004 to June 2005. Results Among these patients, 219 and 154 patients suffered from psoriasis (3.53%) and vitiligo (2.48%), respectively, and 12 patients (0.19%) had psoriasis and vitiligo simultaneously. The coincidence in the psoriasis group was 5.48% and in the vitiligo group was 7.79%, so the coincidence of both diseases was greater than the incidence of each alone. This association was significant ( p = .004). Conclusion Coincidence of these two diseases was seen, but more studies should be done to find common genetic and immunologic factors.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Ashique, Karalikkattil T., Feroze Kaliyadan und Shimna Iqbal. „Dermabrasion of the Eyelids in Vitiligo Surgery“. Dermatologic Surgery 42, Nr. 5 (Mai 2016): 691–92. http://dx.doi.org/10.1097/dss.0000000000000675.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Ashique, Karalikkattil T., und Chakravarthy R. Srinivas. „Resizing blister roof grafts for vitiligo surgery“. Journal of the American Academy of Dermatology 71, Nr. 2 (August 2014): e39-e40. http://dx.doi.org/10.1016/j.jaad.2014.02.008.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Sharquie, Khalifa E., Adil A. Noaimi und Haitham M. Salmo. „Pityriasis alba versus vitiligo“. Journal of the Saudi Society of Dermatology & Dermatologic Surgery 17, Nr. 2 (Juli 2013): 51–54. http://dx.doi.org/10.1016/j.jssdds.2013.05.002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Yanai, Akira. „Thin minigrafting for stable vitiligo.“ Plastic & Reconstructive Surgery 101, Nr. 6 (Mai 1998): 1760. http://dx.doi.org/10.1097/00006534-199805000-00108.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Gupta, Devendra Kumar, und Shruti Devendra. „Microskin Grafting for Stable Vitiligo of the Penis and Vulva“. Journal of Cutaneous Medicine and Surgery 19, Nr. 5 (20.03.2015): 477–83. http://dx.doi.org/10.1177/1203475415577752.

Der volle Inhalt der Quelle

Annotation:

Background: The vitiligo of the penis and vulva is a difficult to treat region of the body where the existing surgical repigmentation methods usually do not give satisfactory results. Objective: This study was conducted to evaluate the efficacy of microskin grafting in stable genital vitiligo. Methods: Four male patients and 1 female patient were included in this study, and microskin grafting was performed in the stable vitiliginous areas of genitals under regional anaesthesia. Results: The microskin grafting technique has shown desired results at these sites with near total pigmentation and negligible donor area deformity. Conclusion: The microskin grafting for vitiligo is simple, reliable, and the most cost-effective technique of tissue grafting that has all the benefits of the latest cellular grafting techniques without its high cost and infrastructure.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Abdulla, Sonya J., und J. P. DesGroseilliers. „Treatment of Vitiligo with Narrow-Band Ultraviolet B: Advantages and Disadvantages“. Journal of Cutaneous Medicine and Surgery 12, Nr. 4 (Juli 2008): 174–79. http://dx.doi.org/10.2310/7750.2008.07054.

Der volle Inhalt der Quelle

Annotation:

Background: Narrow-band ultraviolet B (NB-UVB) therapy for vitiligo is increasingly used in patients who are unresponsive to other forms of therapy. Objective: This study measures levels of patient and physician satisfaction and the associated advantages and disadvantages of NB-UVB. Methods: A retrospective chart review was conducted of the first 50 patients with vitiligo treated at the Photoderm Clinic in Ottawa, Ontario. Data were obtained from digital photographs and patient charts (n = 50). Results: Percent repigmentation of the face and body was very good compared with the hands and feet (poor = 0-< 33%; good = 33-< 66%; very good = ≥ 66%). The physician and patients were satisfied with results achieved with NB-UVB therapy (very good [VG]: medical doctor [MD] 49% [95% CI 35–63], patient [Pt] 51% [95% CI 37–65]; good [G]: MD 24% [95% CI 12–36], Pt 22% [95% CI 10–34]). Conclusion: NB-UVB therapy is an effective treatment for vitiligo (ie, VG, repigmentation ≥ 66%) that leads to high levels of patient and physician treatment-related satisfaction. Although there are disadvantages to NB-UVB therapy, the advantages outweigh the drawbacks. An objective evaluation such as the Vitiligo Area Scoring Index (VASI) is necessary to validate these findings. Additional limitations include those inherent in retrospective study design.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Pahwa, Manish, Somesh Gupta und Niti Khunger. „Multimodal Single-Step Vitiligo Surgery: A Novel Approach“. Dermatologic Surgery 36, Nr. 10 (Oktober 2010): 1627–31. http://dx.doi.org/10.1111/j.1524-4725.2010.01697.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Chouhan, Kavish, Amrendra Kumar und AmrinderJ Kanwar. „Body hair transplantation in vitiligo“. Journal of Cutaneous and Aesthetic Surgery 6, Nr. 2 (2013): 111. http://dx.doi.org/10.4103/0974-2077.112675.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

AlGhamdi, Khalid M., und Noura A. Moussa. „Mercury Levels in Vitiligo Patients“. Journal of Cutaneous Medicine and Surgery 15, Nr. 6 (November 2011): 358–59. http://dx.doi.org/10.2310/7750.2011.11042.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

KAHN, ARTHUR M., und MYLES J. COHEN. „Repigmentation in Vitiligo Patients“. Dermatologic Surgery 24, Nr. 3 (März 1998): 365–67. http://dx.doi.org/10.1111/j.1524-4725.1998.tb04168.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Kahn, Arthur M. „Surgical Treatment of Vitiligo“. Dermatologic Surgery 25, Nr. 8 (August 1999): 669. http://dx.doi.org/10.1046/j.1524-4725.1999.99093-2.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Achauer, Bruce M., Yuen Le und Victoria M. Vander Kam. „Treatment of Vitiligo with Melanocytic Grafting“. Annals of Plastic Surgery 33, Nr. 6 (Dezember 1994): 644–46. http://dx.doi.org/10.1097/00000637-199412000-00015.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Isedeh, Prescilia, Ahmed Al Issa, Henry W. Lim, Smita S. Mulekar und Sanjeev V. Mulekar. „Uncommon Responses of Segmental Vitiligo to Melanocyte-Keratinocyte Transplantation Procedure“. Journal of Cutaneous Medicine and Surgery 19, Nr. 2 (März 2015): 177–81. http://dx.doi.org/10.2310/7750.2014.14061.

Der volle Inhalt der Quelle

Annotation:

Background Patients with segmental vitiligo (SV), unlike those with nonsegmental vitiligo (NSV), have a more predictable course and are more responsive to surgery. Objective To report 10 patients with SV treated with the melanocyte-keratinocyte transplantation procedure (MKTP), who responded with unusual responses not previously reported in the literature. Methods This is a retrospective, observational study that reports 10 patients with SV who underwent the MKTP between May 2003 and May 2012. Results Two patients had successful repigmentation after split-thickness skin grafting after failure of the MKTP. Two patients developed a hypopigmented ring at a margin of the MKTP-treated area. One patient had complete repigmentation after a second MKTP. Two patients developed koebnerization of the recipient site. Three patients developed new vitiligo patches in previously unaffected areas after the MKTP. Conclusions Uncommon and even suboptimal responses can occur following the MKTP in SV patients. There is a need for studies to provide better understanding and outcomes for SV patients undergoing the MKTP.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Thakur, Vishal, Vignesh Narayan R, Keshavamurthy Vinay und Sunil Dogra. „Surgical modalities of treatment in vitiligo“. Cosmoderma 1 (10.06.2021): 13. http://dx.doi.org/10.25259/csdm_18_2021.

Der volle Inhalt der Quelle

Annotation:

Vitiligo is an acquired disorder of depigmentation that is associated with immense stigma and psychological burden. Although there is a myriad of options available for therapy, the repigmentation is best achieved with surgical modalities for stable disease. Once the immune attack on melanocyte is halted, surgery can be undertaken. The principles of surgery may be to introduce artificial pigment, stimulate melanocyte proliferation and migration, removal of depigmented areas or repopulation of depleted melanocytes. Broadly these can be divided into grafting, non-grafting techniques, camouflage and excision. The grafting techniques are further divided into cellular and tissue grafts. The advantage of the former being a greater donor to recipient ratio, however with added cost and equipment requirement. Grafting techniques have undergone various innovations, be it in harvesting, recipient site preparation or dressing, each with their own advantages and disadvantages. New innovations continue to crop up, including the use of stem cells and regulatory T-cell modulation. A well performed surgery is incomplete if it was not done without proper patient selection, counseling and preparation. This review article briefly outlines the various techniques; pre, intra and post-operative intricacies and the innovations in each.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Dash, R., A. Mohapatra und B. S. Manjunathswamy. „Anti-Thyroid Peroxidase Antibody in Vitiligo: A Prevalence Study“. Journal of Thyroid Research 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/192736.

Der volle Inhalt der Quelle

Annotation:

Aim.The aim of the study was to study the relation of vitiligo with demographic data like age, sex, and duration and determine the prevalence of thyroid autoimmunity in vitiligo patients.Materials and Methods.This study was a cross sectional study consisting of 100 patients clinically diagnosed (old and new) as having vitiligo irrespective of age or sex. Patients with known thyroid disease on supplementation therapy, or who had undergone thyroid surgery, those on antithyroid medication, patients with other causes of leukoderma, and cases who do not provide informed consent were excluded from the study. Serum TSH and anti-TPO antibodies were measured in all the patients.Results.The prevalence of anti-TPO antibody positivity was found to be 28%.Conclusion.According to our study, none of our vitiligo patients had symptoms or signs of thyroid disease at the time of presentation but, on biochemical evaluation, anti-TPO antibodies were found in a considerable number of patients. Hence, we recommend screening of these patients with thyroid antibodies.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Lahiri, Koushik. „Stability in vitiligo? what′s that?“ Journal of Cutaneous and Aesthetic Surgery 2, Nr. 1 (2009): 38. http://dx.doi.org/10.4103/0974-2077.53100.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Khunger, Niti, SushrutaDash Kathuria und V. Ramesh. „Tissue grafts in vitiligo surgery - past, present, and future“. Indian Journal of Dermatology 54, Nr. 2 (2009): 150. http://dx.doi.org/10.4103/0019-5154.53196.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

AGRAWAL, KAROON, und APARNA AGRAWAL. „Vitiligo: Surgical Repigmentation of Leukotrichia“. Dermatologic Surgery 21, Nr. 8 (August 1995): 711–15. http://dx.doi.org/10.1111/j.1524-4725.1995.tb00275.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Boen, Monica, Monique J. Vanaman Wilson, Douglas C. Wu und Mitchel P. Goldman. „Laser Depigmentation in Extensive Vitiligo“. Dermatologic Surgery 45, Nr. 4 (April 2019): 621–23. http://dx.doi.org/10.1097/dss.0000000000001597.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Falabella, Rafael. „Surgical Approaches for Stable Vitiligo“. Dermatologic Surgery 31, Nr. 10 (Oktober 2005): 1277–84. http://dx.doi.org/10.1097/00042728-200510000-00003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Falabella, Rafael. „Surgical Approaches for Stable Vitiligo“. Dermatologic Surgery 31, Nr. 10 (21.03.2006): 1277–84. http://dx.doi.org/10.1111/j.1524-4725.2005.31203.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Gou, Darlene, Sharif Currimbhoy und Amit G. Pandya. „Suction Blister Grafting for Vitiligo“. Dermatologic Surgery 41, Nr. 5 (Mai 2015): 633–39. http://dx.doi.org/10.1097/dss.0000000000000341.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Moore, Mark H. „Localized Vitiligo and Frontoethmoidal Meningoencephalocele“. Journal of Craniofacial Surgery 8, Nr. 1 (Januar 1997): 78–79. http://dx.doi.org/10.1097/00001665-199701000-00024.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Patel, Nishit S., Kapila V. Paghdal und George F. Cohen. „Advanced Treatment Modalities for Vitiligo“. Dermatologic Surgery 38, Nr. 3 (März 2012): 381–91. http://dx.doi.org/10.1111/j.1524-4725.2011.02234.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Kanwar, Amrinder J., Rahul Mahajan und Davinder Parsad. „Low-Dose Oral Mini-Pulse Dexamethasone Therapy in Progressive Unstable Vitiligo“. Journal of Cutaneous Medicine and Surgery 17, Nr. 4 (Juli 2013): 259–68. http://dx.doi.org/10.2310/7750.2013.12053.

Der volle Inhalt der Quelle

Annotation:

Background: The course of vitiligo is unpredictable. If the disease is spreading rapidly, the progression can be controlled with the use of systemic steroids daily or in pulsed form. The present study was planned to assess the efficacy of low-dose dexamethasone oral mini-pulse therapy in progressive unstable vitiligo. Materials and Methods: In this retrospective study, the case records of patients with vitiligo during the period from January 2006 to December 2010 were studied. Patients who had progressive unstable disease were included. These patients were administered oral dexamethasone 2.5 mg per day on 2 consecutive days after breakfast in a week. The patients were asked to come for regular follow-up to assess the arrest of disease activity, relapse of disease activity, and adverse effects. Results: A total of 444 patients were analyzed. In 408 (91.8%) patients, arrest of disease activity was achieved at a mean duration of 13.2 ± 3.1 weeks. In addition, some repigmentation of the lesions was seen in all patients after a mean of 16.1 ± 5.9 weeks. During the follow-up, 50 of 408 (12.25%) patients experienced one or two episodes of relapse in disease activity, which were treated with reinstitution of low-dose dexamethasone oral mini-pulse therapy. The mean disease-free survival (DFS) until the first relapse was 55.7 ± 26.7 weeks, and the mean DFS until the second relapse was 43.8 ± 7.2 weeks. Adverse reactions such as weight gain, lethargy, and acneiform eruptions were observed in 41 (9.2%) patients. Conclusion: Low-dose oral mini-pulse dexamethasone therapy is a good option for arresting progressive unstable vitiligo with minimal adverse effects.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!